BioAdvance News

Melior Pharmaceuticals Announces Positive Results in Phase 2B Study with Tolimidone for Type 2 Diabetes

By WebmasterMay 14, 2019November 1st, 2024No Comments

Melior Pharmaceuticals Announces Positive Results in Phase 2B Study with Tolimidone for Type 2 Diabetes
• Tolimidone treatment significantly reduced HbA1c compared to placebo
• Company makes strategic decision to move tolimidone into NASH development

See more here

Previous PostPillo Health Raises $11M in Series-A Funding from Stanley Black & Decker and Samsung Ventures to Fuel Development of Voice-First Healthcare Platform for the Home
Next PostRelmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results

Melior Pharmaceuticals Announces Positive Results in Phase 2B Study with Tolimidone for Type 2 Diabetes

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostPillo Health Raises $11M in Series-A Funding from Stanley Black & Decker and Samsung Ventures to Fuel Development of Voice-First Healthcare Platform for the Home

Next PostRelmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results